FCCC LOGO Faculty Publications
Han LC , Kim SP , Gross CP , Ross JS , Van Houten HK , Smaldone MC , Krambeck AE , Shah ND
Association of physician specialty and medical therapy for benign prostatic hyperplasia
Med Care. 2014 Feb;52(2) :128-36
Back to previous list
Abstract
BACKGROUND: Despite little available evidence to determine whether recently introduced selective alpha-1 blockers and 5-alpha reductase inhibitors (5-ARIs) are superior to the existing agents in treating benign prostatic hyperplasia (BPH), they are being increasingly prescribed. OBJECTIVE: To describe the prescribing patterns of new and existing agents among patients with incident BPH after the introduction of several new agents and determine whether these varied by physician specialty. RESEARCH DESIGN: We analyzed a retrospective cohort from an administrative claims database from January 2004 through December 2010. SUBJECTS: Patients diagnosed with incident BPH aged 40 years and above and those who received medical management. MEASURES: Receipt of medical therapy for incident BPH (ie, selective alpha-1 blockers [prazosin (released 1976), terazosin (1987), doxazosin (1990), tamsulosin (1997), alfuzosin (2003), silodosin (2009)] and 5-ARIs [finasteride (1992) and dutasteride (2002)]). RESULTS: A total of 42,769 men with incident BPH received any selective alpha-1 blocker or 5-ARI. Tamsulosin and dutasteride were the most widely prescribed agents of their respective drug classes. Predicted probabilities showed that urologists were more likely to prescribe alfuzosin (24.0% vs. 7.8%; P<0.001) and silodosin (2.3% vs. 0.4%; P<0.001) when compared with primary care providers (PCPs) at 6 months after diagnosis. Urologists were more likely to prescribe 5-ARIs but less likely to prescribe older alpha-1 blockers (terazosin, prazosin, and doxazosin) than PCPs at 6 months postdiagnosis. CONCLUSIONS: Among insured patients diagnosed with BPH, our study suggests that the overall use of new agents is rising. In particular, urologists were more likely to prescribe newer selective alpha-1 blockers compared with PCPs.
Notes
Han, Leona C Kim, Simon P Gross, Cary P Ross, Joseph S Van Houten, Holly K Smaldone, Marc C Krambeck, Amy E Shah, Nilay D United States Med Care. 2014 Feb;52(2):128-36. doi: 10.1097/MLR.0000000000000078.